# Michael Friedländer

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/michael-friedlander/

## Facts

| Field | Value |
| --- | --- |
| Citations | 64,755 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 103 |
| i10-index | 450 |
| Last Known Institution | Royal Hospital for Women |
| OpenAlex ID | https://openalex.org/A5021894535 |
| ORCID iD | 0000-0003-3090-795X |
| Works | 942 |

## Researcher papers

Showing 12 of 19.

- [Risks of Breast, Ovarian, and Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers](https://scholariq.org/papers/risks-of-breast-ovarian-and-contralateral-breast-cancer-for-i-brca1-i-and-i/)
- [Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer](https://scholariq.org/papers/maintenance-olaparib-in-patients-with-newly-diagnosed-advanced-ovarian-cancer/)
- [Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial](https://scholariq.org/papers/oral-poly-adp-ribose-polymerase-inhibitor-olaparib-in-patients-with-brca1-or/)
- [Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry.](https://scholariq.org/papers/method-for-analysis-of-cellular-dna-content-of-paraffin-embedded-pathological/)
- [Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer](https://scholariq.org/papers/olaparib-maintenance-therapy-in-platinum-sensitive-relapsed-ovarian-cancer/)
- [Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/olaparib-tablets-as-maintenance-therapy-in-patients-with-platinum-sensitive/)
- [Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/rucaparib-maintenance-treatment-for-recurrent-ovarian-carcinoma-after-response/)
- [Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation](https://scholariq.org/papers/olaparib-monotherapy-in-patients-with-advanced-cancer-and-a-germline-i-brca1-2-i/)
- [Whole–genome characterization of chemoresistant ovarian cancer](https://scholariq.org/papers/whole-genome-characterization-of-chemoresistant-ovarian-cancer/)
- [Rethinking ovarian cancer: recommendations for improving outcomes](https://scholariq.org/papers/rethinking-ovarian-cancer-recommendations-for-improving-outcomes/)
- [Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer](https://scholariq.org/papers/veliparib-with-first-line-chemotherapy-and-as-maintenance-therapy-in-ovarian/)
- [Chemotherapy‐induced peripheral neurotoxicity: A critical analysis](https://scholariq.org/papers/chemotherapy-induced-peripheral-neurotoxicity-a-critical-analysis/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

## Researcher university

- [Royal Hospital for Women](https://scholariq.org/institutions/royal-hospital-for-women/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.